secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tvardi Therapeutics, Inc. (TVRD)
CIK:        0001346830
Form:       8-K
Filed at:   2024-08-01T23:59:59+00:00
Accession:  0001104659-24-084911
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Cara Therapeutics gets Nasdaq extension to Jan 2025 to regain $1 bid price; stock moved to Capital Market
--------------------------------------------------------------------------------

- Nasdaq granted 180-day extension, until January 27, 2025, to meet minimum $1.00 closing bid price for 10 consecutive business days.
- Company's common stock transferred from Nasdaq Global Market to Nasdaq Capital Market effective August 1, 2024.
- If compliance not achieved by deadline, Nasdaq will delist; company may appeal to a Nasdaq Hearings Panel.
- Company will monitor bid price and consider options including a reverse stock split to regain compliance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1346830/000110465924084911/0001104659-24-084911-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1346830/000110465924084911/tm2420653d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-084911

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer